Robert L. Tirva

Robert L. Tirva, listed as finance chief, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Broadcom Corp, DNA X, Inc. and Resonant Inc. Between 5 August 2008 and 15 July 2022, the trades on record add up to 66 filings.

Market trades split into 1 purchase (€66k) and 16 sales (€2.8M). Sales outweigh purchases by €2.7M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 39 share grants and 9 option exercises. So far in 2022, the count stands at no purchases and 4 sales.

On 15 July 2022 came the latest disclosure, an open-market sale for €552 in DNA X, Inc. The most recent open-market purchase was published on 11 June 2020, 2,326 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.